Alumis and Acelyrin had merger talks in 2023 before current deal. SEC filing shows earlier reverse merger attempt, followed ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

Acelyrin (NASDAQ:SLRN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...

ACELYRIN, INC. has announced that its Board of Directors has determined that an unsolicited proposal from Concentra Biosciences is unlikely to lead to a better offer than its planned all-stock ...

March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading ...

Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company. The late-stage biopharma said ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...